The Jerusalem PostThird US aircraft carrier enters Middle East as Trump heads to China for talks with Xi, PutinCNN TürkKYK BURSU NE ZAMAN YATACAK 2026: KYK bursu ödeme takvimi belli oldu mu?InquirerDole releases payment rules for Asean Summit holidaysZDF heuteEntdecken Sie das ZDF-Nachrichtenstudio매일경제트럼프 방문 앞두고 마닐라 ‘난장판’…시위대 수백명 체포Daily MailAde Adepitan says I'm A Celebrity jungle is 'more accessible than London' after bespoke changes - and reveals Cyclone ambition for his sonStraits Times SportAustralians Zoric, Ewing take world surfing games goldCollider10 Great Fantasy Movies That Come Close to Perfectionالشرقأرملة رئيس هايتي الراحل تسجل ترشحها لأول انتخابات منذ عقدNew Straits TimesPotential OPR hike to boost banks' NIM, Public Bank set to gain mostThe Sydney Morning Herald‘Not some controlling monster’: Elizabeth Holmes’ partner gives first interview since doco releaseMintIMD weather update: Andhra, Odisha on high alert as third cyclone brews over Bay of Bengal in 3 weeks
The Daily Newsstand · Free, Always
Monday, November 16, 2026

[특징주] HLB테라퓨틱스 하한가…각막염 치료제 3상서 1차 지표 미충족

Translate

HLB테라퓨틱스가 신경영양성각막염 치료제 후보물질 ‘RGN-259’의 임상 3상에서 1차 평가변수를 충족하지 못했다는 소식에 16일 장 초반 하한가를 기록했다. 이날 오전 9시 27분 기준 코스닥시장에서 HLB테라퓨틱스는 전 거래일보다 700원(29.98%) 내린 1635원에 거래되고 있다. HLB테라퓨틱스는 미국 자회사 리젠트리가 진행한 임상 3상(SEE

Read the full article on 조선일보 →

KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.